Description: Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey.
Home Page: www.outlooktherapeutics.com
OTLK Technical Analysis
Building F
Iselin,
NJ
08852
United States
Phone:
609 619 3990
Officers
| Name | Title |
|---|---|
| Mr. Ralph H. Thurman | Independent Exec. Chairman |
| Mr. C. Russell Trenary III | Pres, CEO & Director |
| Mr. Lawrence A. Kenyon CPA | Exec. VP, CFO, Treasurer, Company Sec. & Director |
| Mr. Terry Dagnon | Chief Operations Officer |
| Mr. Jeffrey Evanson | Chief Commercial Officer |
| Rick Gregory | Director of Marketing & Communications |
| Ms. Alicia Tozier | Sr. VP, Marketing & Market Access |
| Mr. Joel Prieve | Sr. VP of Commercial Operations |
| Dr. Balu N. Balasubramanian Ph.D. | Advisor |
| Ms. Elizabeth A. Yamashita | Advisor |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 10.1912 |
| Price-to-Sales TTM: | 13.2716 |
| IPO Date: | 2016-05-13 |
| Fiscal Year End: | September |
| Full Time Employees: | 17 |